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Antiphospholipid Antibodies and Valve
Disease in Patients With Systemic
Lupus Erythematosus
Roldan et al . (l) are to he congratulated on their study of heart valve
disease in patients with systemic lupus erythematosus . The large
number of patients involved and their use of high resolution trans-
esophageal echocardiography to detect valve abnormalities make
this an important contribution . However, several methodologic
considerations limit the ability to draw conclusions regarding the
possible pathogenic role of antiphospholipid antibodies in the devel-
opment of heart valve disease in the study patients .
1 . The authors compared the prevalence of heart valve disease
between the total of patients with systemic lupus erythematosus
who test positive for antiphospholipid antibodies (Group 1) and
those who test negative (Group 11) without taking into accuunt the
level of positivity . They concluded that there was no apparent
justification for considering antiphospholipid antibodies to be a risk
factor for heart valve disease in these patients . The Second Inter-
national Anticardiolipin Standardization Workshop recommended
that only moderately and highly positive serum values be considered
clinically relevant (2). Thus, Roldan et al . may have diluted their
antibody-positive group of patients with low risk patients . How
many of their 22 patients with lupus and positive antiphospholipid
antibodies had moderate to high serum levels? Of those with
moderate to high levels, how many had significant heart valve
disease? With the use of two-dimensional transthoracic echocardi-
ography in our own prospective studies (3,4) and in those of other
investigators (5-7), a statistically significant association was found
between antiphospholipid antibodies and heart valve disease, both
in patients with systemic lupus erythematosus and in those with the
primary antiphospholipid syndrome .
2 . The authors did not provide details of the methods used to
measure antiphospholipid antibodies in their study . It was recently
suggested (8,9) that antiphospholipid antibodies in autoimmune
diseases require a cofactor for maximal binding to cardiolipin in the
enzyme-linked immunoabsorbenl assay (ELISA) system . This co-
factor has been identified as beta-2 glycoprotein I (apolipoprotein
H), a normal plasma protein with a serum concentration of
-200 pg/ml (9) . The use of 10% adult or fetal bovine serum in
phosphate-buffered saline solution as diluent for the test serum
would provide enough cofactor for anticardiolipin antibodies to have
maximal binding (10) . This fundamental technical issue should be
clarified before final conclusions can be drawn from this study .
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Reply
Khamashta and Hughes raise two important issues regarding our
study of valve disease in patients with systemic lupus erythemato-
sus. The first concerns the antiphospholipid antibody measurement
technique.
The IgG and 1gM anticardiolipin antibodies were measured by a
standardized enzymatic immunosorbent assay (ELISA) using 10%
adult bovine serum as a diluent and expressed in international units
(IU) (1,2) .
The second concerns the relation between the level of anticar-
diolipin antibody positivity versus the incidence of valve disease .
The IgG positivity was categorized as: absent = <8 IU, I+
positive = 8 to 19 LU, 2+ positive = 20 to 49 IU, 3+ positive = 50
to 79 IU, 4+ positive = >80 IU . For IgM, absent = <10 IU, I+
positive = 10 to 19 IU, 2+ positive = 20 to 29 IU, 3+ positive = 30
to 591U, and 4 r positive = >60 I(.' . Nineteen patients with lupus
and nine patients with antiphospholipid syndrome had IgG or 1gM
anticardiolipin antibodies, or both . The mean concentration of IgG
and 1gM antibodies in the two groups was similar : 59 ± 61 IU and 34
24 IU and 65 ± 35 IU and 40 ± 22 LU, respectively . There was no
association between the highest positivity level of either igG or 1gM
antibodies and the frequency of valve abnormalities in both groups
(Table 1).
Table 1. Correlation of Antibody (AB) Positivity and Valve
Disease (VD) in Patients With Systemic Lupus Erytheinatosus
(SLE) or Antiphospholipid Syndrome (APS)
AB Positivity
SLE +AB
(VD/n)
APS
(VD/n)
1+ 416
1/2
2+ 415
0 /(1
3+
3/4 2/3
4+
414
014
